The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Open accessPublished version of a preprint
Abstract
The phosphoinositide 3-kinase (PI3K)/AKT and RAF/MEK/ERK signaling pathways are activated in a wide range of human cancers. In many cases, concomitant inhibition of both pathways is necessary to block proliferation and induce cell death and tumor shrinkage. Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a parallel signaling pathway, thereby decreasing the effectiveness of single-agent targeted therapies. In this study, we describe a feedback mechanism in which MEK inhibition leads to activation of PI3K/AKT signaling in EGFR and HER2-driven cancers. We found that MEK inhibitor–induced activation of PI3K/AKT resulted from hyperactivation of ERBB3 as a result of the loss of an inhibitory threonine phosphorylation in the conserved juxtamembrane domains of EGFR and HER2. Mutation of this amino acid led to increased ERBB receptor activation and upregulation of the ERBB3/PI3K/AKT signaling pathway, which was no longer responsive to MEK inhibition. Taken together, these results elucidate an important, dominant feedback network regulating central oncogenic pathways in human cancer. Cancer Res; 72(13); 3228–37. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inhibition of either PI3K/mTOR or ERK signaling often relieves feedback inhibition of the other and causes its activation46,47.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [47]
In the citing paper
“In NSCLCs and CRCs, KRASG12C inhibition leads to an accumulation of activated upstream EGFR and/or other ERBB family members, which facilitates escape from KRASG12C-inhibitor monotherapy110,121–124.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Self-citationmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Self-citationPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Self-citationAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Jura, N., Endres, N., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 609
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578
Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 541
Cited by
Sorted by citations
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Self-citationA Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
The PI3K/AKT/mTOR interactive pathway
Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015) · Molecular BioSystems · doi:10.1039/c5mb00101c · Cited by 683
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 652
Negative feedback regulation of the ERK1/2 MAPK pathway
Lake, D., Corrêa, S. A. L., & Müller, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2297-8 · Cited by 565
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Hu, K., Li, K., Lv, J., Feng, J., Chen, J., Wu, H., Cheng, F., Jiang, W., Wang, J., Pei, H., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124049 · Cited by 409
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 410
Rozengurt, E., Soares, H. P., & Sinnet-Smith, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0330 · Cited by 317
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 269
Self-citationPI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 215
ERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
Ras and Rap1: A tale of two GTPases
Shah, S. K., Brock, E. J., Ji, K., & Mattingly, R. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 217
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
Tricker, E. M., Xu, C., Uddin, S., Capelletti, M., Ercan, D., Ogino, A., Pratilas, C. A., Rosen, N. X., Gray, N. S., Wong, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0063 · Cited by 220
Learning single-cell perturbation responses using neural optimal transport
Bunne, C., Stark, S. G., Gut, G., del Castillo, J. S., Levesque, M., Lehmann, K.-V., Pelkmans, L., Krause, A., & Rätsch, G. (2023) · Nature Methods · doi:10.1038/s41592-023-01969-x · Cited by 202
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
Gibney, G. T., Messina, J. L., Smalley, I., Sondak, V. K., & Smalley, K. S. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.83 · Cited by 199
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
MEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 198
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J. M., & Piccart, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 184
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Leary, M., Heerboth, S. A., LAPINSKA, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 171
Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 168
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Dumble, M. L., Crouthamel, M., Zhang, S., Schaber, M. D., Levy, D. S., Robell, K. A., Liu, Q., Figueroa, D. J., Minthorn, E. A., Seefeld, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100880 · Cited by 150
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 141
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D. E., Lin, J., Reddy, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000305 · Cited by 147
Roberts, P. J., Usary, J., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., Duncan, J. S., Johnson, S. M., Combest, A. J., Jin, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0563 · Cited by 147
Do, K. T., Speranza, G., Bishop, R. J., Khin, S. A., Rubinstein, L., Kinders, R. J., Datiles, M. B., Eugeni, M. A., Lam, M. H., Doyle, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0212-z · Cited by 133
Butler, D. E., Marlein, C. R., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T., & Maitland, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18082 · Cited by 136
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang‐Gillam, A., & Cox, A. D. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 133
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 125
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas
Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R. E., Cai, Y., Behrens, C., Dellinger, M. T., Brekken, R. A., Wistuba, I. I., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0388 · Cited by 114
Ammad-ud-din, M., Khan, S. A., Malani, D., Murumägi, A., Kallioniemi, O., Aittokallio, T. A., & Samuel Kaski, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw433 · Cited by 116
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 118
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T. S., Seo, C., Merlino, G. T., & Yu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0205-4 · Cited by 115
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 110
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V. M., Xu, L., Kohli, N., Rennard, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 106
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 107
Smith, T., Affram, K., Nottingham, E., Han, B., Amissah, F., Krishnan, S., Trevino, J. G., & Agyare, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-73218-6 · Cited by 98
Xia, G., Wang, H., Song, Z., Meng, Q., Huang, X., & Huang, X. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0579-0 · Cited by 100
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Wang, J., Hu, K., Guo, J., Cheng, F., Lv, J., Jiang, W., Lü, W., Liu, J., Pang, X., & Liu, M. (2016) · Nature Communications · doi:10.1038/ncomms11363 · Cited by 97
Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00776-6 · Cited by 90
Shiau, J., Chuang, Y.-T., Tang, J., Yang, K., Chang, F., Hou, M., Yen, C., & Chang, H. (2022) · Antioxidants · doi:10.3390/antiox11091845 · Cited by 97
Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80
Carter, C. A., Rajan, A., Keen, C., Szabo, E. M., Khozin, S., Thomas, A., Brzezniak, C. E., Guha, U., Doyle, L. A., Steinberg, S. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw008 · Cited by 89
Cushman, S. M., Jiang, C., Hatch, A. J., Shterev, I. D., Sibley, A. B., Niedzwiecki, D., Venook, A. P., Owzar, K., Hurwitz, H. I., & Nixon, A. B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2313 · Cited by 84
Pettazzoni, P., Viale, A., Shah, P. K., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 83
Mazumdar, T., Byers, L. A., Ng, P. K. S., Mills, G. B., Peng, S., Diao, L., Fan, Y.-H., Stemke‐Hale, K., Heymach, J. V., Myers, J. N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1090 · Cited by 79
Sanlorenzo, M., Choudhry, A., Vujic, I., Posch, C., Kim, C. A., Johnston, K., Meier, M. M., Osella‐Abate, S., Quaglino, P., DAUD, A. I., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.09.002 · Cited by 78
Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 74
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
Sandhöfer, N., Metzeler, K. H., Rothenberg, M., Herold, T., Tiedt, S., Groiß, V., Carlet, M., Walter, G., Hinrichsen, T., Wachter, O., et al. (2014) · Leukemia · doi:10.1038/leu.2014.305 · Cited by 75
MEK inhibitors under development for treatment of non-small-cell lung cancer
Kim, C. G., & Giaccone, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415324 · Cited by 73
Fu, X., Creighton, C. J., Biswal, N. C., Kumar, V., Shea, M. J., Herrera, S., Contreras, A., Gutiérrez, C., Wang, T., Nanda, S., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0430-x · Cited by 73
Adaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 73
Vakana, E., Pratt, S. E., Blosser, W. D., Dowless, M. S., Simpson, N., Yuan, X., Jaken, S., Manro, J. R., Stephens, J. R., Zhang, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14002 · Cited by 72
Gendelman, R., Xing, H., Mirzoeva, O. K., Sarde, P., Curtis, C. N., Feiler, H. S., MCDONAGH, P. D., Gray, J. W., Khalil, I. G., & Korn, W. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0512 · Cited by 70
Sato, H., Yamamoto, H., Sakaguchi, M., Shien, K., Tomida, S., Shien, T., Ikeda, H., Hatono, M., Torigoe, H., Namba, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13763 · Cited by 72
Ponz‐Sarvisé, M., Corbo, V., Tiriac, H., Engle, D. D., Frese, K. K., Oni, T. E., Hwang, C., Öhlund, D., Chio, I. I. C., Baker, L. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1398 · Cited by 65
Choi, C., & Helfman, D. M. (2013) · Oncogene · doi:10.1038/onc.2013.341 · Cited by 67
Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells
Chivu‐Economescu, M., Dragu, D., Necula, L. G., Matei, L., Enciu, A., Bleoţu, C., & Diaconu, C. C. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0712-y · Cited by 65
Chen, C., Hsia, T., Yeh, M., Chen, T.-H., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12102 · Cited by 65
Spreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3140 · Cited by 64
Rocca, A., Braga, L., Volpe, M. C., Maiocchi, S., & Generali, D. (2022) · Cancers · doi:10.3390/cancers14215306 · Cited by 71
Interleukin‐1β orchestrates underlying inflammatory responses in microglia via Krüppel‐like factor 4
Kaushik, D. K., Thounaojam, M. C., Kumawat, K. L., Gupta, M., & Basu, A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12382 · Cited by 63
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
Ludwik, K. A., Campbell, J. P., Li, M., Li, Y., Sandusky, Z. M., Pasic, L., Sowder, M. E., Brenin, D. R., Pietenpol, J. A., O'Doherty, G. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0106 · Cited by 63
Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
Wu, K., Chang, Q., Lu, Y., Qiu, P., Chen, B., Thakur, C., Sun, J., Li, L., Kowluru, A., & Chen, F. (2013) · Oncotarget · doi:10.18632/oncotarget.1431 · Cited by 62
Wu, L. Y., Maachani, U. B., Schweitzer, M. E., Singh, R., Wang, M., Chang, R. Y., & Souweidane, M. M. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.12.008 · Cited by 63
McNeill, R. S., Canoutas, D. A., Stuhlmiller, T. J., Dhruv, H., Irvin, D., Bash, R., Angus, S. P., Herring, L. E., Simon, J. M., Skinner, K., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox044 · Cited by 61
Ewald, F., Nörz, D. S., Grottke, A., Hofmann, B. T., Nashan, B., & Jücker, M. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0149-7 · Cited by 60
Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0145 · Cited by 58
New strategies for targeting kinase networks in cancer
Yesilkanal, A. E., Johnson, G. L., Ramos, A. F., & Rosner, M. R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101128 · Cited by 58
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Nakai, Y., Isayama, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1453 · Cited by 57
Zañudo, J. G. T., Scaltriti, M., & Albert, R. (2017) · Cancer Convergence · doi:10.1186/s41236-017-0007-6 · Cited by 55
Precision drugging of the MAPK pathway in head and neck cancer
Ngan, H.-L., Law, C. H., Choi, Y. C. Y., Chan, J. Y.-S., & Lui, V. W. Y. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00293-1 · Cited by 60
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 58
Vena, F., Causi, E. L., Rodriguez‐Justo, M., Goodstal, S. M., Hagemann, T., Hartley, J. A., & Hochhauser, D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0485 · Cited by 56
Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 56
The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
Mandel, A., Larsson, P., Sarwar, M., Semenas, J., Khaja, A. S. S., & Persson, J. L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0035-4 · Cited by 53
Recent advances in HER2-targeted delivery for cancer therapy
Dhritlahre, R. K., & Saneja, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.014 · Cited by 53
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
Yao, W.-L., Yue, P., Zhang, G.-J., Owonikoko, T., Khuri, F., & Sun, S.-Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.028 · Cited by 51
Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1
Xie, X., Tang, S.-C., Cai, Y., Pi, W., Deng, L., Wu, G., Chavanieu, A., & Teng, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11185 · Cited by 49
Umapathy, G., Guan, J., Gustafsson, D. E., Javanmardi, N., Cervantes-Madrid, D., Djos, A., Martinsson, T., Palmer, R. H., & Hallberg, B. (2017) · Science Signaling · doi:10.1126/scisignal.aam7550 · Cited by 52
Vetter, M. H., & Hays, J. L. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.01.012 · Cited by 50
SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
del Río, I. B., Young, L. C., Sarı, S., Jones, G. G., Ringham-Terry, B., Hartig, N., Rejnowicz, E., Lei, W., Bhamra, A., Šurinová, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902658116 · Cited by 47
Kirouac, D. C., Du, J., Lahdenranta, J., Onsum, M. D., Nielsen, U. B., Schoeberl, B., & McDonagh, C. F. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004827 · Cited by 49
Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Chen, M., Peters, A., Huang, T., & Nan, X. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001152212 · Cited by 49
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
Graham, D. M., Coyle, V. M., Kennedy, R. D., & Wilson, R. H. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0312-y · Cited by 49
Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer
He, Q., Xue, S., Tan, Y., Zhang, L., Shao, Q., Xing, L., Li, Y., Xiang, T., Luo, X., & Ren, G. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.004 · Cited by 47
Adaptive resistance to targeted therapies in cancer.
Rosell, R., Karachaliou, N., Morales-Espinosa, D., Costa, C., Molina‐Vila, M. Á., Sansano, I., Gascó, A., Viteri, S., Massutí, B., Wei, J., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.08 · Cited by 48
Self-citationThe role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Gillson, J., Ramaswamy, Y., Singh, G., Gorfe, A. A., Pavlakis, N., Samra, J. S., Mittal, A., & Sahni, S. (2020) · Cancers · doi:10.3390/cancers12051341 · Cited by 45
Schoumacher, M., Hurov, K. E., Lehár, J., Yan‐Neale, Y., Mishina, Y. M., Sonkin, D., Korn, J. M., Flemming, D., Jones, M. D., Antonakos, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0138-t · Cited by 46
Metadata
- Authors
- Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Engelman, Jeffrey A.
- ORCID
- Venue
- Cancer Research
- Published
- 2012-07-01
- Volume
- 72
- Issue
- 13
- Pages
- 3228-3237
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3515079
- OpenAlex
- W2105437003
- Cited by
- 368
- References
- 37
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 22 · 2023: 30 · 2022: 32 · 2021: 21 · 2020: 27 · 2019: 25 · 2018: 27 · 2017: 30 · 2016: 36 · 2015: 25 · 2014: 30 · 2013: 18 · 2012: 3
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50 CA98131, R01 CA80195, P50CA127003, R01CA166480, U01CA141457, R01CA080195, R01CA140594, P50CA090578, K08CA120060, P50CA098131, P01CA120964, R01CA137008, P30CA006516)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- MEK inhibition, PI3K/Akt signaling, HER3, ErbB receptors, EGFR, HER2, negative feedback loop, Raf/MEK/ERK pathway, drug resistance, cancer pathways
- MeSH terms
- Cell Line, Enzyme Activation, Feedback, Flow Cytometry, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinase Kinases, Proto-Oncogene Proteins c-akt, Tandem Mass Spectrometry, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
